Mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia.
作者信息
Sutton Lesley-Ann
机构信息
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
出版信息
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000240. eCollection 2019 Jun.
Abstract
摘要
相似文献
1
Mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia.慢性淋巴细胞白血病中靶向治疗耐药的机制
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000240. eCollection 2019 Jun.
2
Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中靶向治疗耐药机制
Handb Exp Pharmacol. 2018;249:203-229. doi: 10.1007/164_2017_12.
3
Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中靶向药物的耐药机制。
Cancer J. 2019 Nov/Dec;25(6):428-435. doi: 10.1097/PPO.0000000000000406.
4
Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.慢性淋巴细胞白血病和靶向治疗时代的感染风险：将机制与感染联系起来。
Blood Rev. 2018 Sep;32(5):387-399. doi: 10.1016/j.blre.2018.03.004. Epub 2018 Mar 16.
5
Genomics of Resistance to Targeted Therapies.靶向治疗耐药性的基因组学。
Hematol Oncol Clin North Am. 2021 Aug;35(4):715-724. doi: 10.1016/j.hoc.2021.03.004. Epub 2021 May 26.
6
Advances in the therapy of chronic lymphocytic leukemia.慢性淋巴细胞白血病的治疗进展
Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008.
7
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.扩大慢性淋巴细胞白血病的治疗手段：慢性淋巴细胞白血病治疗中新型药物的综述
J Oncol Pharm Pract. 2017 Oct;23(7):502-517. doi: 10.1177/1078155216656929. Epub 2016 Jun 29.
8
Chronic lymphocytic leukemia.慢性淋巴细胞白血病
Curr Opin Hematol. 1999 Jul;6(4):253-61. doi: 10.1097/00062752-199907000-00010.
9
[Multidrug resistance in chronic lymphocytic leukemia].
Orv Hetil. 2008 Jan 27;149(4):161-7. doi: 10.1556/OH.2008.28203.
10
[Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].新型靶向治疗时代慢性淋巴细胞白血病的治疗策略
Rinsho Ketsueki. 2020;61(9):1275-1280. doi: 10.11406/rinketsu.61.1275.
引用本文的文献
1
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.接受新型药物治疗的慢性淋巴细胞白血病患者的耐药相关突变
Front Oncol. 2020 Jun 25;10:894. doi: 10.3389/fonc.2020.00894. eCollection 2020.
本文引用的文献
1
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.复发性 Gly101Val 突变的获得使慢性淋巴细胞白血病患者对 Venetoclax 产生耐药性。
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
2
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.慢性淋巴细胞白血病中对维奈托克耐药性发展的克隆动力学
Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.
3
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.依鲁替尼复发的慢性淋巴细胞白血病患者白血病进展和里氏转化背后的克隆进化
Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9.
4
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.在既往治疗的 CLL/SLL 患者中，3 期 RESONATE 研究中高危预后因素的延长随访及影响。
Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.
5
BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶介导的慢性淋巴细胞白血病对依鲁替尼的耐药性
J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.
6
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.在接受依鲁替尼治疗的慢性淋巴细胞白血病中，PLCG2 C2结构域突变与BTK及PLCG2耐药突变同时出现。
Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3.
7
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.导致慢性淋巴细胞白血病对伊布替尼耐药的克隆进化。
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
8
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.慢性淋巴细胞白血病患者对 BTK 抑制产生耐药性后的克隆进化。
Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.
9
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
10
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
Zotero 插件